SOURCE: Imaging3, Inc.

Imaging3, Inc.

April 12, 2011 07:00 ET

Imaging3, Inc. Outlines FDA Resubmission Strategy for Its 3D Real-Time Imaging Device

BURBANK, CA--(Marketwire - Apr 12, 2011) - Imaging3™, Inc. (OTCBB: IMGG), developer of a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time, announced that the company's Chairman and CEO Dean Janes was interviewed on Thursday, April 7, 2011, on MoneyTV, a business and investment oriented television program. The interview focused on the company's three phased approach for its FDA 510(k) submission for the Dominion Volumetric Imaging Scanner (DViS).

Mr. Janes commented that the company has finalized its general resubmission strategy after a thorough review with the company's FDA legal and technical consulting team. Implementation of the strategy involves the following three phased approach: First, the development of protocols for collecting comparison imaging data. Second, with the assistance of the consultant team, meet with the FDA to present the protocols with the goal of reaching consensus with the Agency to help ensure a viable resubmission. The third and final phase is the acquisition of images based on the approved imaging protocols and combining those images and data with the overall package and final submission to the FDA.

The MoneyTV Episode can be viewed using these links (http://www.moneytv.net/imgg14.mov, http://www.moneytv.net/volume15week14.htm) and will be available on the Imaging3 website soon.

About Imaging3
Imaging3, Inc., founded in 1993, is a leading provider of advanced technology medical imaging devices. The Company has developed a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time. Because these 3D images are instantly constructed in real-time, they can be used for any current or new medical procedures in which multiple frames of reference are required to perform medical procedures on or in the human body. Visit the company's website at http://www.imaging3.com for more information

Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, technological obsolescence, competition from other medical instrument(s) and imaging companies, lack of capital, unexpected costs, failure or delay of FDA approval, absence of revenue, the impact on the national and local economies resulting from an economic recession or terrorist actions, and U.S. actions subsequently; unavailability of financing for the Company or its customers, product malfunction and potential product liability claims, and other factors detailed in reports filed by the Company.

Contact Information

  • Contact:
    Imaging3, Inc.
    Investor Relations
    800-900-9729